Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTSExpanding access to home-use technologies can help bridge the healthcare gap and advance health equity. However, there are challenges and opportunities associated with developing, evaluating, and monitoring home-use technologies, such as ensuring usability, reliability, connectivity, security, privacy, and patient safety. The Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) released a request for public comments titled, Increasing Patient Access to At-Home Use of Medical Technologies, consistent with its efforts to advance health equity.
IQVIA is actively involved is designing and conducting clinical studies and patient adherence programs that utilize at-home and remote medical devices, encompassing both the pre-market and post-market activities. Given our experience in this area and passion for advancing health equity, a group of IQVIA data scientists and subject matter experts discussed the Agency's concerns and prepared a written response. This document conveys our general thinking and answers to the FDA's eight specific questions.